FDA approves Bayer/J&J's stroke drug Xarelto
(Reuters) - U.S. health regulators approved on Friday the stroke preventer Xarelto from Bayer AG and Johnson & Johnson for people with a common heart rhythm disorder known as atrial fibrillation....
View ArticleAblynx regains nanobody rights from Pfizer
BRUSSELS (Reuters) - Belgian biotech firm Ablynx said on Friday that it had regained the rights for its TNF-Alpha targeting nanobodies from Pfizer, which form the basis of a rheumatoid arthritis...
View ArticleMcKesson ExpressRx Track plan increases efficiency and prescription volume
McKesson High Volume Solutions will introduce ExpressRx Track this week in New Orleans at the 46th American Society of Health-system Pharmacists Midyear Clinical Meeting and Exhibition. The ExpressRx...
View ArticlePredicting adverse drug reactions
Researchers at Children’s Hospital Boston have created a new mathematical model that combines multiple forms of widely available data to predict adverse drug events (ADEs). This new method may be able...
View ArticleSilk microneedles painlessly deliver controlled-release drugs
Bioengineers at Tufts University School of Engineering have developed a silk-based microneedle able to deliver precise drug amounts over a set time. In addition, these new silk microneedles inhibited...
View ArticleNanoparticles could deliver drugs to the brain
Researchers at the University of Buffalo (UB) have released results indicating that ORMOSIL (organically modified silica) nanoparticles could be used to deliver drugs. Each nanoparticle is a vessel,...
View ArticlePutting the brakes on cocaine addiction
Researchers have discovered a brain mechanism that limits the rewarding sensations of cocaine. Recent research with rodents implicated histone deacetylases (HDACs), which are modulators of gene...
View ArticleResearchers develop new mechanism of drug release over an extended period
Researchers at Brigham and Women’s Hospital in Boston, Mass. have developed a new mechanism of drug release. It uses 3D superhydrophobic materials that make use of air as a removable barrier, which...
View ArticleDrugs: 'New' does not always mean 'better'
Cases in which a newly approved drug is more effective than the cheaper alternatives already available are the exceptions rather than the rule. This is the conclusion reached in new study in the...
View ArticleNew process could make malaria drug less costly
Scientists have developed a process that would make the most effective anti-malarial treatment less costly. The new technique makes it easier to produce artemisinin combination therapy (ACT) which...
View ArticleState Department, Universities Blast UN Attack on Patents
If the UN Secretary General and the members of his “High Level Panel on Access to Medicines” thought the State Department was bluffing when it warned against their attempt to make intellectual...
View ArticleVanda v. Roxane Labs. – Are Two Natural Laws Better Than One?
As you will recall, in Prometheus v. Mayo, the Supreme Court held that a claim reciting a natural law had to have other non-conventional steps to pass muster under s. 101. The natural law in Mayo was...
View ArticleWinning the Drug Development Debate
The stage is being set for a coordinated attack on the patent system under the guise of making international health care more affordable. A newly released United Nations report encourages developing...
View ArticlePatexia Insight 112: ANDA Litigation is Declining
A couple of weeks ago we released our second annual ANDA Litigation Intelligence Report where we covered the rankings, statistics, and comprehensive analysis of ANDA and Hatch-Waxman stakeholders. We...
View ArticleHow Do Patents Affect The Healthcare Industry?
Global health care spending is predicted to reach $10 trillion USD during 2022 with almost 30% of it belonging to the USA. It might sound like a good industry to be in, but keep in mind that the costs...
View ArticleUS Senators Demand Measures From USPTO to Combat Pharma Patent Thickets
Last week, a bipartisan group of six U.S. senators sent a letter to USPTO asking to take measures in order to combat patent thickets coming from pharmaceutical companies. Republican senators John...
View ArticleCureVac Files Patent Infringement Lawsuit in Germany Against BioNTech
Two weeks ago, Curevac filed a lawsuit in the German Regional Court in Düsseldorf against BioNTech over patent infringement alleging that BioNTech’s Covid-19 vaccine infringed its patents related to...
View ArticleThe Benefits and Effects of Hatch- Waxman Act Four Decades Later
In early 1983, Bolar Pharmaceutical Inc. wanted to bring a generic version of the Dalmane drug, a sleeping pill, to the market. At that time, Roche Products Inc. held patent rights for flurazepam...
View ArticlePatexia Insight 148: ANDA Litigation Grows in the First Half of 2022
This morning we released our third annual ANDA Litigation Intelligence Report. The report covers high-level statistics related to Hatch-Waxman litigation including the analysis of the outcomes, most...
View ArticleThe U.S. Supreme Court is About to Ultimately Decide Amgen vs Sanofi Antibody...
Most of the community involved in life science litigation and pharmaceutical companies, thought they saw the end of the long-fought battle between Amgen and Sanofi in 2021 with the CAFC decision. As a...
View Article
